Leadership

  • Seong-Jin Kim PhD Chief Executive Officer
    Seong-Jin Kim was the first scientist to identify the deletion and mutation of TGF-β receptor genes in cancer cells.
    He has published over 290 studies regarding cancer, inflammation and TGF-β in Nature and other journals, and has been cited over 4,200 times. He was also the first to decode the Korean genome sequence. Recent Inverviews

    Career

    • CEO, MedPacto, Inc.
    • Director, Precision Medicine Research Center, Advanced Institute of Convergence Technology of Seoul National University, Korea
    • Visiting Professor, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    • Visiting Professor, Tsukuba University, Japan
    • Vice Chairman/CSO, TheragenEtex Co.
    • Advisor, National Cancer Center, Korea
    • Director, Cancer Research Institute, Distinguished Professor of Medicine, CHA University of Medicine and Science
    • President, CHA Research Institutes, CHA University of Medicine and Science
    • Director, Lee Gil Ya Cancer and Diabetes Research Institute, Lee Gil Ya Distinguished Professor of Medicine, Gachon University of Medicine and Science
    • Senior Investigator (Tenured Principal Investigator), Head, Gene Regulation Group, Laboratory of Cell Regulation and Carcinogenesis (Former Laboratory of Chemoprevention), NCI, NIH
    • Chief, Cancer Cell Signaling Section, Laboratory of Cancer Biology and Genetics, NCI, NIH

    Honors and Awards

    • 2002 Ho-Am Prize in Medicine
    • 2007 Gangwondo Prize
    • 2008 Sangrock Prize in Science
    • 2011 Dongkok Prize
    • 2011 Peru Congressional Medal
    • 2015 Gold Ribbon Lecture
    • 2017 Japan Cancer Association International Award

    Publications and Presentations

    • Destablilization of TRAF6 by DRAK1 suppresses tumor growth and metastasis in cervical cancer cells. Cancer Res. in press, 2020 Apr.
    • RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers. Nature Communications. 2019 Dec.
    • Co-Chaperone BAG2 Determines Pro-Oncogenic Role of Cathepsin B in Triple-Negative Breast Cancer Cells. Cell Reports. 2017 Dec.
    • Nutrient signaling linked to dipeptide uptake sustains long-term maintenance of CML stem cells. Nature Communications. 2015 Aug.
    • DRAK2, a Novel TGF-b1-Inducible Protein, Participates in a Negative Feedback Loop to Control TGF-b/Smads Signaling by Binding to Type I TGF-b Receptor. Cell Reports. 2012 Nov.
    • Smad7 binds to TAB2 and TAB3 to block recruitment of the TAK1 complex to TRAF2. Nature Immunology. 2007 Jun.
    • Smad6 negatively regulates Interleukin 1-Receptor/Toll-like receptor signals by disruption of the IRAK-1-mediated signaling complex through binding to Pellino-1: A novel function of Smad6 as an anti-inflammatory mediator. Nature Immunology. 2006 Oct.
    • The EWS-FLI1 oncogene of Ewing sarcoma represses TGF-b type II receptor gene expression. Nature Genetics. 1999 Oct.
    • Genetic changes in the transforming growth factor ß (TGF-ß) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-b. Proc. Natl. Acad. Sci. USA 1994 Sep.
    • Retinoblastoma gene product activates expression of the human TGF-b2 gene through transcription factor ATF‑2. Nature. 1992 Jul.
    • Autoinduction of TGF-b1 is mediated by the AP‑1 complex. Mol. Cell. Biol. 1990 Apr.
  • Ki Baik Hahm MD, PhD Executive Vice President , R&D
    Ki-Baik Hahm is the Executive Vice President of R&D at MedPacto and a recognized authority in the fields of gastritis, gastric ulcer, gastric cancer and colorectal cancer. He served as a Professor of Internal Medicine at Ajou University and CHA University. With extensive experience in clinical research, he leads MedPacto’s new drug development and clinical trials.

    Career

    • EVP of R&D, MedPacto, Inc.
    • President, International Conference on Ulcer Research
    • Representative, Korea Research-driven Hospital
    • Vice-Chair, Gastrointestinal, IUPHAR
    • International Director, The Japanese Gastroenterology Association
    • Professor, Internal Medicine, Cha University Bundang Medical Center
    • Professor CHA Bio Complex Professor, Internal Medicine, College of Medicine, Gachon University
    • Professor Lee Gil Ya Cancer and Diabetes Institute
    • Chief Director, Human Genome Research & Bioresearch Center, Ajou University Hospital
    • Professor, Internal Medicine, College of Medicine, Ajou University
    • Postdoctoral Fellow, NCI/NIH
    • Full-time lecturer, Internal Medicine, College of Medicine, Yonsei University
    • Intern & Resident, Severance Hospital

    Publications and Presentations

    • Management of Gastroesophageal Reflux Disease in Asian Countries: Results of a Questionnaire Survey. Digestion. 2020 Jan.
    • Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia. J Clin Biochem Nutr. 2019 Sept.
    • Antioxidant therapy in chronic pancreatitis-promises and pitfalls. Ann Transl Med. 2019 Jul.
    • Umbilical cord/placenta-derived mesenchymal stem cells inhibit fibrogenic activation in human intestinal myofibroblasts via inhibition of myocardin-related transcription factor A. Stem Cell Res Ther. 2019 Sept.
    • Periodontitis is associated with an increased risk for proximal colorectal neoplasms. Sci Rep. 2019 May.
    • Combination Therapy with a PI3K/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein-Barr Virus-Infected Gastric Cancer Cells. Mol Cells. 2019 Jun.
  • Dong-In Yook PhD Executive Vice President
    Dong-In Yook is the Executive Vice President at MedPacto and in charge of external collaborations and public relations. Prior to joining MedPacto, he was a Reporter for the Korea Economic Daily for over 20 years, Spokesperson for the Financial Services Commission and Head of The Blue House Press Center.

    Career

    • EVP, MedPacto, Inc.
    • Invited Professor, Kangwon National University
    • Head, The Blue House Press Center
    • Spokesman, Financial Services Commission
    • CEO, CareerCare
    • Public Information Officer, National Assembly Secretariat
    • Editorialist, New York–based correspondent, Korea Economic Daily
  • Seon-Jeong Kim KICPA Chief Financial Officer
    Seon-Jeong Kim is the CFO at MedPacto and a Certified Public Accountant. He had experience working as a accountant and consultant for over 25years.

    Career

    • CFO, Head of Management Support Division, MedPacto, Inc.
    • Head of QRM / Partner, Dasan Account Corporation (DAC)
    • Advisor, Korea Communications Agency & Ministry of Science and ICT
    • Member, Broadcasting Evaluation Committee, Korea Communication Commission
    • Member, KASB Advisory Council, Korea Accounting Institute
    • Member, Accounting Audit Committee, Korean Accounting Association
    • Member, Ethics Investigation Deliberative Committee, KICPA
    • Supervisor, Samil PricewaterhouseCoopers Korea

    Honors and Awards

    • 2011 Commissioner’s Award, Financial Services Commission
  • Sunjin Hwang MD Chief Medical Officer
    Sunjin Hwang is the CMO and joined MedPacto from Gilead Korea, where he was the Country Medical Director. Sunjin leads the clinical development of vactosertib.

    Career

    • CMO, MedPacto, Inc.
    • Country Medical Director, Gilead
    • Medical Advisor, MSD
    • Resident & Fellow, Department of Family Medicine, Seoul Samsung Medical Center
    • Intern, Seoul Asan Medical Center

    Publications and Presentations

    • Preclinical Studies and Phase I Trial of Vactosertib in combination with pomalidomide in relapsed multiple myeloma (ASH2019)
    • Population Pharmacokinetics of vactosertib, a new TGF-β receptor type I inhibitor, in patients with advanced solid tumors (Cancer Chemotherapy and Pharmacology)
    • Clinical ALK5 inhibitor, Vactosertib, reverses TGF-β stimulated Smad-2 driven ineffective hematopoiesis in MDS (ASH2019)
    • Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with pembrolizumab in patients with metastatic colorectal or gastric cancer (SITC 2019)
    • Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with durvalumab in patients with advanced non-small cell lung cancer(NSCLC) (SITC2019)
    • Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase I study (Invest New Drugs 2019)
    • Population pharmacokinetics of a novel TGF- β receptor I kinase inhibitor Vactosertib in patients with advanced-stage solid tumors (ASCPT2019)
  • Jung-Im Huh PhD Discovery Lead
    Jung-Im Huh is an Executive Director at MedPacto and in charge of discovering and verifying novel therapeutic candidates. After specializing in pharmacy, she was a postdoctoral researcher at the National Cancer Institute (NCI/NIH).

    Career

    • Executive Director/ Lead of Discovery, MedPacto, Inc.
    • Executive Director, Corestem Inc
    • Manager, Product Ehs&R, 3M Korea
    • Adjunct Professor, University of Science and Technology
    • Senior Research Scientist, Korea Institute of Toxicology
    • Staff Scientist, The Wistar Institute/University of Pennsylvania
    • Postdoctoral Fellow, NCI/NIH

    Publications and Presentations

    • Assessing the safety of an Ephedrae Herba Aqueous extract in rats : A repeat dose toxicity study. Regul Toxicol pharmacol. 2018 Apr.
    • Cytotoxicity and sub-acute toxicity in Crl:CD(SD) rats of traditional herbal formula Ojeok-san. BMC Complement Altern Med. 2015 Mar.
    • Subacute Oral Toxicity of Yukmijiwhang-Tang in Crl:CD Sprague-Dawley Rats and Its Cytotoxicity. Evid Based Complement Alternat Med. 2014 Nov.
    • Protective effect of Bojungkki-tang, a traditional herbal formula against alcohol-induced gastric injury in rats. J Ethnopharmacol. 2012 Jul.
    • In vitro and in vivo evaluation of the genotoxicity of Gumiganghwal-tang, a traditional herbal prescription. J Ethnopharmacol. 2012 May.
    • Antisense Inhibition of Coagulation Factor XI Prolongs APTT without Increased Bleeding Risk in Cynomolgus Monkeys. Blood. 2012 Mar.
  • Dong-Woo Kang PhD Development Lead
    Dong-Woo Kang is a Director at MedPacto. As the lead, Dong Woo specialized in anti-cancer therapeutic development, developing new pipelines and strategizing combination therapy of immune checkpoint inhibitor anti-cancer drugs.

    Career

    • Director / Lead of Development, MedPacto, Inc.
    • Assistant Professor, College of Medicine, University of Ulsan
    • Research Assistant Professor, Seoul Asan Medical Center
    • Research Fellow, Pusan Nat’l University

    Publications and Presentations

    • Phospholipase D1 inhibition, linked to upregulation of ICAT, blocks colorectal cancer growth hyperactivated by Wnt/β-catenin and PI3K/Akt Signaling. Clin Cancer Res 23. 2017 Sep.
    • MicroRNA-320a and -4496 attenuate Helicobacter pylori CagA-induced cancer-initiating potential and chemo-resistance by targeting β-catenin and ABCG2. J Pathol. 2017 Feb.
    • Phospholipase D1 acts through Akt/TopB1 and RB1 to regulate the E2F1-dependent apoptotic program in cancer cells. Cancer Res. 2017 Jan.
    • Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of β-catenin signaling axis in gastric cancer-initiating cells. Biochem Pharmacol. 2016 Aug.
    • Targeting Phospholipase D1 Attenuates Intestinal Tumorigenesis by Controlling β-catenin Signaling in Cancer-Initiating Cells. J Exp Med. 2015 Jul.
  • Min-Woo Kim CMC Lead
    Min-Woo Kim is a Director at MedPacto leading CMC activities based on his work experience at GC Pharma and Genexine. He oversees antibody and CMC development and manages partnerships with CDMOs.

    Career

    • Director, MedPacto, Inc.
    • Specialist, Purification Team, Genexine
    • Principal investigator, GC-Research Center
    • Senior Researcher, MOGAM Institute for Biomedical Research

    Honors and Awards

    • 2018 the first annual Korea Biopharmaceutical Awards (Global Challenge Prize)

    Publications and Presentations

    • An antifungal property of Burkholderia ambifaria against phytopathogenic fungi. Microbiol, Biotechnol, 2006.
    • A conformational study in solution of protein kinase C alpha(19-35) by NMR spectroscopy. Journal of Peptide science, 2005.
    • Naltriben analogues as peptide anticancer drugs. Microbiol, Biotechnol, 2004 Aug.
    • Anti-fungal activity of streptomyces sp. Against Puccinia recondite causing wheat leaf rust. Microbiol, Biotechnol, 2004.
    • Production of a rice 16 for NMR structure determination. Protein Exp. Puri, 2004.

Scientific Advisory Board

  • John Letterio MD
    John Letterio is an expert in TGF-β signaling, principally in its activity at the interface between inflammation and cancer. He also developed of the first bi-dentate inhibitor of Cdk5 and discovered the role of Cdk5 as a modulator of immune checkpoint molecules and an agent for tumor treatment.

    Career

    • Associate Director, Seidman Cancer Center, University Hospitals Cleveland Medical Center
    • Co-Director, Developmental Therapeutics Program, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine
    • Scientific Advisory Board, Hyundai Hope on Wheels Foundation, Hyundai Motor Cars, America
    • Director, Angie Fowler Adolescent & Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children’s Hospital (UH RB&C)
    • Director, Center for Survivors of Childhood Cancer, University Hospitals Rainbow Babies & Children’s Hospital (UH RB&C)
    • Advisor, Case Research Institute (CRI) Advisory Board (CWRU)
    • Pediatric Disease Team Leader, Case Comprehensive Cancer Center
    • Professor, Department of Pharmacology, Case Western Reserve University
    • Professor, Department of Pediatrics, Case Western Reserve University
    • Chief, Division of Pediatric Hematology / Oncology University Hospitals Rainbow Babies & Children’s Hospital (UH RB&C)
    • Principal Investigator, Lab of Immunoregulation Laboratory of Cell Regulation and Carcinogenesis, NCI, NIH
    • Adjunct Senior Staff; Clinical Oncology Fellow, Pediatric Oncology Branch, NCI, NIH
    • Pediatrics, Intern and Resident, Rainbow Babies & Children’s Hospital, Case Western Reserve University School of Medicine (CWRU)
    • Fellow, The Stanley J. Sarnoff Society for Cardiovascular Science CVRI, University of California, San Francisco

    Honors and Awards

    • 1995 American Association for Cancer Research, Bristol-Myers Travel Award
    • 1997 NCI, Division of Clinical Sciences Intramural Research Award
    • 2000 NCI, Division of Basic Sciences Collaborative Project Award “TGF-β Signaling Pathways in Self-Renewal, Growth and Differentiation of Hematopoietic Stem Cells”
    • 2003 NCI Intramural Research Award  “Inhibitors of TGF-β signaling: augmenting hematopoietic recovery following myelosuppressive chemotherapy”.
    • 2004 Technology Transfer Award, CCR, National Cancer Institute
    • 2006 The Jane & Lee Seidman Chair in Pediatric Cancer Innovation
    • 2017 The HDI Scholar Innovator Award

    Publications and Presentations

    • Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 2016 Jul.
    • Smad4 signaling in T cells is required for suppression of gastrointestinal cancer. Nature. 2006 Jun.
    • Loss of Smad3 in acute T-cell lymphoblastic leukemia. The New England journal of medicine. 2004 Aug.
    • Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature cell biology. 1999 Aug.
    • Regulation of immune responses by TGF-beta. Annual review of immunology. 1998 Apr.
    • Transforming growth factor-beta 1 is a new form of tumor suppressor with true haploid insufficiency. Nature medicine. 1998 July.
    • Maternal rescue of transforming growth factor-beta 1 null mice. Science. 1994 Jun.
  • Hanlim Moon MD, PhD CEO, Connect Clinical Sciences
    Hanlim Moon was a Professor of Hemato-oncology at The Catholic University of Korea, and served as a Medical Director for big pharma such as Sanofi-Aventis Korea and Korea GSK. Currently, she specializes in consulting on clinical development as a co-CEO of Connect Clinical Science, and also advises on MedPacto’s various pipelines.

    Career

    • CEO, Conncect Clinical Sciences
    • Fully independent Consultant, Oncology Expert, CUREnCARE Research
    • Head, Medical Affairs, Mundipharma Pte Ltd(Emerging Market Region)
    • Vice President, ADM Korea
    • Head of Clinical Development, OxOnc Inc., President of OxOnc Korea
    • Oncology Medical Director, China and Asia, Oncology R&D, GlaxoSmithKline
    • Senior Director, Oncology Medical Franchise, International and Asia-Pacific Region, Sanofi-Aventis
    • Director, Oncology Medical Franchise, Aventis Pharma
    • Research Fellow, National Institute of Allergy and Infectious Diseases(NIAID), NIH
    • Professor, College of Medicine, Catholic University of Korea (Major : Haemato-oncology)

    Publications and Presentations

    • CTCF is conserved from Drosophila to Man and confers enhancer blocking of the Fab-8 insulator. EMBO Rep. 2005 Feb.
    • Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC Cancer. 2012 Jul.
    • Brain metastases in Asian HER-2 positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. 2012 Sep.
    • Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. Oncol Rep. 2013 Aug.
    • Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries. Cancer Med. 2015 Aug.
    • Clinical development consulting during early drug development process in Korea. TCP. 2019 Mar.
  • Seock-Ah Im MD, PhD Professor of College of Medicine (Internal Medicine) , Seoul National University

Board of Directors